TGTX vs ZBH
TG Therapeutics, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
TGTX
TG Therapeutics, Inc.
60
Watch
VS
| Metric | TGTX | ZBH |
|---|
| AI Score |
60
|
69
|
| Price |
$49.86
|
$97.22
|
| P/E Ratio |
16.39×
|
23.54×
|
| ROE |
69.0%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
82.4%
|
69.9%
|
| Debt / Equity |
1.25×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
42.0
|
63.1
|
| Beta |
1.666
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for TGTX versus ZBH.
ZBH leads by 9 points.
ZBH scores 69/100 (Buy) versus TGTX at 60/100 (Watch).
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical